SIGA publishes investor presentation on TPOXX smallpox antiviral franchise and growth strategy

SIGA Technologies outlined a strategy to extend its TPOXX smallpox franchise through new indications, including post-exposure prophylaxis, and new formulations.

Presentation highlighted TPOXX regulatory clearances across the U.S., Canada, Europe, the UK, and Japan, positioning it as a core biodefense product.

Company cited about $980 million in product revenue during 2020-2025, citing robust gross margins and about $390 million in pre-tax operating income.

Government contracting remained central, with BARDA procurement contracts totaling $1.01 billion across 2011-2018 and 2018-2026, both fully delivered.

Balance sheet messaging emphasized disciplined cash use, no debt, and a $43 million cash dividend paid in 2026.